MedTrace Logo

Artemisinin Resistance in Bangladesh

NCT00639873 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2013-08-23

No results posted yet for this study

Summary

A randomized, controlled clinical trial conducted in Southeastern Bangladesh using artesunate monotherapy to determine the baseline sensitivity of P. falciparum to artemisinins.

Conditions

Interventions

DRUG

Artesunate

2 or 4 mg/kg/day for 7 days

DRUG

quinine-doxycycline

quinine-doxycycline for 7 days

Sponsors & Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Harald Noedl, MD, PhD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • Bangladesh

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00639873 on ClinicalTrials.gov